OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
January 11, 2024
Lutathera is indicated for patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs.
Study investigates the gaps in access to this service, and how internet service impacts telehealth use.
Manufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.
SELLAS Life Sciences Group, Inc’s CDK9 inhibitor SLS009 is being evaluated in combination with Venclexta (venetoclax) and Vidaza (azacytidine) for patients with relapsed or refractory acute myeloid leukemia.
January 10, 2024
The novel therapy in development to treat breast cancer and ovarian cancer is a formulation of a well-established freeze-dried powder medication that has been in use dating back to the 1950s.
Acquisition is expected to offer life sciences clients a boost in expertise and insight.
At the 42nd annual JP Morgan Healthcare Conference, Moderna said new product launches later this year will return the company to sales growth in 2025.
Lutikizumab is an investigational, dual-variable-domain IL 1α/1β antagonist to Phase III for the treatment of hidradenitis suppurativa.
January 09, 2024
Review article explores the latest developments surrounding expression and purification strategies.
Astellas said it will work closely with the FDA and a third-party manufacturer to develop a timeline that will quickly resolve feedback from the complete response letter to a Biologics License Application for zolbetuximab.